1 of 3
FEATURED COMPANIES
- Denali Therapeutics
- E-Scape Bio
- Ionis Pharmaceuticals
- Neuron23
- Voronoi
- MORE
This “LRRK2 inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in LRRK2 inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
LRRK2 inhibitor: Overview
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.
Report Highlights
This segment of the LRRK2 inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
LRRK2 inhibitor Emerging Drugs
LRRK2 inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different LRRK2 inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on LRRK2 inhibitor
There are approx. 8+ key companies which are developing the LRRK2 inhibitor. The companies which have their LRRK2 inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.
The report covers around 10+ products under different phases of clinical development like
LRRK2 inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses LRRK2 inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging LRRK2 inhibitor drugs.
LRRK2 inhibitor Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
LRRK2 inhibitor: Overview
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence LRRK2 inhibitor R&D. The therapies under development are focused on novel approaches for LRRK2 inhibitor.
This segment of the LRRK2 inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
LRRK2 inhibitor Emerging Drugs
- ION859: Ionis Pharmaceuticals
- DNL151: Denali Therapeutics
LRRK2 inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different LRRK2 inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on LRRK2 inhibitor
There are approx. 8+ key companies which are developing the LRRK2 inhibitor. The companies which have their LRRK2 inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.
The report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
LRRK2 inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses LRRK2 inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging LRRK2 inhibitor drugs.
LRRK2 inhibitor Report Insights
- LRRK2 inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing LRRK2 inhibitor drugs?
- How many LRRK2 inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for LRRK2 inhibitor?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the LRRK2 inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for LRRK2 inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ionis Pharmaceuticals
- Denali Therapeutics
- Neuron23
- Voronoi
- E-Scape Bio
- ION859
- DNL151
- Small molecule therapeutics
- VRN-01
- ESB-5070
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Denali Therapeutics
- E-Scape Bio
- Ionis Pharmaceuticals
- Neuron23
- Voronoi
- MORE
Introduction
Executive Summary
LRRK2 inhibitor: Overview
In-depth Commercial Assessment
LRRK2 inhibitor Key Products
LRRK2 inhibitor - Unmet Needs
LRRK2 inhibitor - Market Drivers and Barriers
LRRK2 inhibitor - Future Perspectives and Conclusion
LRRK2 inhibitor Analyst Views
LRRK2 inhibitor Key Companies
Appendix
List of Tables
Table 1 Total Products for LRRK2 inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for LRRK2 inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
LRRK2 inhibitor: Overview
- Structure
- Mechanism of Action
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- LRRK2 inhibitor companies' collaborations, Licensing, Acquisition - Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
LRRK2 inhibitor Key Products
LRRK2 inhibitor - Unmet Needs
LRRK2 inhibitor - Market Drivers and Barriers
LRRK2 inhibitor - Future Perspectives and Conclusion
LRRK2 inhibitor Analyst Views
LRRK2 inhibitor Key Companies
Appendix
List of Tables
Table 1 Total Products for LRRK2 inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for LRRK2 inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
- Ionis Pharmaceuticals
- Denali Therapeutics
- Neuron23
- Voronoi
- E-Scape Bio
Note: Product cover images may vary from those shown
